INTRODUCTION
Alcohol is known to have widespread effects on the small intestine 1 and chronic alcohol abuse is often associated with liver disease.2 While there are a few studies available which examine the effect of either alcoholism or liver disease on gastroenteropancreatic hormones,3 16 there are none which attempt to separate the effects of alcoholism from the effects of the frequently concurrent liver disease which in itself will distort the results due to decreased liver metabolism, blood flow and porto-systemic shunting.
disease on fasting and post-prandial glucose, and release of the gastroenteropancreatic hormones studied, which were gastrin, insulin, pancreatic polypeptide (PP), gastric inhibitory polypeptide (GIP), glucagon N, glucagon C and vasoactive intestinal polypeptide (VIP).
MATERIALS AND METHODS
Thirty-two alcoholic subjects (all less than 70 years), with alcohol consumption of greater than 150g/day for five or more years, were divided into a group of 13 patients (12 male and one female) with liver disease, and a group of 19 patients (18 male and one female) without liver disease. Of the 13 patients with liver disease eight had a liver biopsy and the remaining five were diagnosed as having liver disease on the basis of five to seven liver function tests which were greater than three standard deviations from the mean, (increased serum gamma glutamyl transferase, aspartate transaminase, alanine transaminase, alkaline phosphatase, bilirubin, or a reduction in the prothrombin time and serum pseudocholinesterase). The 19 patients without liver disease had all liver function tests (including gamma glutamyl transferase) and were within normal limits, (two standard deviations from the mean). Patients with intermediate liver function tests were excluded from the study. The study had approval of the Research Ethical Committee of the Faculty of Medicine, The Queen's University of Belfast. Liver biopsy was not performed on the 19 patients without evidence of liver disease. All alcoholic patients had an alcohol intake estimated from their history of alcohol consumption during the previous five years and particularly during the preceding week. Two control groups were used in the study. A group of 1 7 normal volunteers (14 male and three female) from the staff and students of the hospital, all less than 70 years old, were studied. They did not have any systemic illness, were on no medication and their individual alcohol consumption was less than 1Og/day. A further control group of 10 patients (six male and four female) with nonalcoholic liver disease were studied. These patients, all of whom had a liver biopsy, included three with primary biliary cirrhosis, three with chronic active hepatitis, three with idiopathic cirrhosis and one with methotrexate-induced cirrhosis. Alcoholic patients were studied within 48 hours of admission to hospital. All subjects were fasted overnight from 10 pm prior to study. At 9 pm on the day of study each subject had an intravenous cannula secured in a forearm vein, and an initial blood sample was taken for glucose and gastroenteropancreatic hormone analysis. After 15 minutes a second fasting sample was taken from all subjects, before a standardised meal was given. The meal used in this study consisted of 60g ham, 60g white bread, 15g butter, 1 00ml orange juice and one cup of tea. This contained 50g carbohydrate, 18g protein and 20g fat and had an energy value of 450 kcalories. This meal was given at time 0 minutes and blood samples were taken at times, 15, 30, 45, 60, 90 and 120 minutes. The cannula was flushed out after each sample with physiological saline (0.9% NaC1). The first 3ml of each sample was discarded to prevent contamination with saline. All hormone samples were immediately transferred to cooled heparinised tubes and kept on ice before centrifugation at the end of the study. All blood samples were analysed for glucose insulin, gastrin, gastric inhibitory polypeptide (GIP), and pancreatic polypeptide (PP). In addition the fasting samples were analysed for N-terminal glucagon, C-terminal glucagon and vasoactive intestinal polypeptide (VIP). All hormones were analysed by radioimmunoassay using methods previously established in the Department of Medicine, The Queen's University of Belfast.1720 The results were analysed non-parametrically using the Wilcoxon rank sum test.
RESULTS
The mean age of the patients with alcoholic liver disease was 46 years (range 28-65 years); that of the patients without alcoholic liver disease 43 years (range 21-69 years); of those with non-alcoholic liver disease 57 years (range 21.69 years), and of the normal volunteers 45 years (range 19-69 years). There were no significant differences between any of these groups. The mean estimated daily alcohol consumption of the alcoholics with liver disease was 235g /day (range 1 50-400g/day) and that of the alcoholics without liver disease was 300g/day (range 1 50-750g/day) (N.S.). Only one patient with non-alcoholic cirrhosis drank alcohol (1 0g/day). The mean alcohol consumption in the normal volunteers was 5g/day (range 0-10g/day). The alcoholics with liver disease had been drinking for a mean of 19 years (range 5-34 years) and the alcoholics without liver disease had been drinking for a mean of 18 years (range 5-42 years). Fasting gastroenteropancreatic hormone and glucose analysis The results of fasting gastroenteropancreatic hormone and glucose analysis are presented in the Table. These fasting results are the average of the two fasting samples taken for each subject. The fasting serum glucose concentrations were higher both in the alcoholics with liver disease and in the patients with non-alcoholic liver disease when compared with the normal volunteers (p<0.0 1). The patients with non-alcoholic liver disease had higher mean fasting gastrin concentrations than either the alcoholics with liver disease (p<0.005) or the normal controls (p<.0.05). The patients with non-alcoholic liver disease had higher fasting plasma insulin concentrations than either the normal volunteers (p< 0.05) or the alcoholics with or without liver disease (p< 0.05). The patients with alcoholic liver disease had higher fasting plasma PP concentrations than either the subjects with non-alcoholic liver disease (p< 0.05) or the normal volunteers (p< 0.05). The alcoholics with liver disease had lower fasting plasma GIP concentrations than the normal volunteers (p<0.05). There were no significant differences noted in fasting plasma N -terminal glucagon or C-terminal concentrations in any of the groups. The patients with non-alcoholic liver disease had higher fasting plasma VIP concentrations than either the alcoholics with liver disease (p< 0.05) or normal controls (p< 0.005).
Post-prandial changes in gastroenteropancreatic hormones and glucose There were significantly higher post-prandial serum glucose concentrations at 120 minutes in the alcoholics with liver disease (6.6 SE ± 0.8 mmol/l) than in the alcoholics without liver disease (4.9 ± 0.4 mmol/l, the patients with non-alcoholic liver disease (5.4 ± 0.8 mmol/l, or the normal controls (4.3 ± 0.2 mmol/l). There were significantly lower post-prandial insulin concentrations in the alcoholics with liver disease (40 ± 8mU/l) than in either the alcoholics without liver disease at 45 minutes (69 ± 7mU/1), the patients with non-alcoholic liver cn~~~~~~~~~~~~( disease at 60 minutes (42 ± 9 mU/I and 87 ± 1 9mU/l) or the normal volunteers at 30 minutes (32 ± 6mU/I and 68 ± 8mU/1). There were lower plasma gastrin concentrations in the alcoholics with liver disease than in the patients with non-alcoholic liver disease at 45 minutes (49 ± 20ng/l and 160 ± 60ng/l, respectively) and at 60 minutes (54 ± 22ng/l and 140 ± 61 ng/l). There was no significant difference in post-prandial plasma gastrin at the recorded times between the alcoholics with and without liver disease and the normal volunteers. There were no significant differences in postprandial plasma concentrations of PP or GIP, between any of the groups.
DISCUSSION
In this paper alcoholics were defined as patients who have consumed more than 150g alcohol per day (approximately 15 measures or two bottles of wine) for five or more years before inclusion in the study. While this definition is arbitrary, most authorities would agree that the patients included were likely to have dependence or harm as a result of their alcohol consumption. The slightly higher mean alcohol consumption in the alcoholics without liver disease than the group with liver disease was not significant, and may be related to a decreased ability in the latter group to metabolise alcohol.
There was evidence of post-prandial glucose intolerance in both groups with liver disease in keeping with previous studies.3 This may be due to a combination of hepatic resistance to the action of insulin and the porto-systemic shunting of both the carbohydrate load and insulin.34 As there was no elevation of the fasting serum glucose concentration in the alcoholics without liver disease, the present data suggests that liver disease was responsible for glucose intolerance noted in alcoholism. Although the patients with non-alcoholic liver disease had fasting hyperinsulinism, plasma insulin concentrations in either alcoholic group were similar to that recorded in the normal volunteers and these findings are in agreement with previous work.4,5 There is a suggestion in the present study that the elevation of fasting plasma insulin concentration is associated with the presence of liver disease (in the subjects with non-alcoholic liver disease) rather than the presence of alcoholism itself as has previously been reported. The fasting plasma PP concentration in both groups with liver disease was higher than in the normal controls, in agreement with previous reports in both alcoholics 9 and subjects with liver failure.8 PP is known to be a strong inhibitor of pancreatic secretion.9 Because up to 40% of alcoholics may have pancreatic exocrine insufficiency, even in the absence of clinical evidence of chronic pancreatitis,'0 some authors have suggested that pancreatic insufficiency may be a result of elevation of PP concentrations.5 However, there was no elevation in PP in the alcoholic subjects without liver disease, and therefore liver disease rather than the presence of alcoholism may be the predominant influence in increasing the fasting plasma concentrations of PP. The reduction in fasting plasma GIP in alcoholics with liver disease when compared with the normal volunteers was not observed in the subjects with nonalcoholic liver disease, suggesting that alcoholism in combination with liver disease reduces GIP concentrations. While the significance of this in unclear, GIP is known to inhibit gastric acid production in animal experiments" 1 and therefore the present reduction in GIP may play a role in the hyperacidity associated with alcohol ingestion.'12 13 N-terminal glucagon release is thought to be a measure of both enteroglucagon and pancreatic glucagon, and C-terminal glucagon is thought to be a measure of pancreatic glucagon. There were no differences noted in either N-or C-terminal glucagon concentrations as a consequence of either alcoholism or liver disease which is in agreement with previous studies.5 An elevation of fasting plasma VIP concentrations in patients with non-alcoholic liver disease compared with controls has been shown previously.14 15, 16 Alcoholism without liver disease, however, had no apparent effect on fasting plasma VIP concentrations. It has been suggested that the elevation of VIP in subjects with liver disease is due to porto-systemic shunting, and this elevation in VIP, while small, may nevertheless be related to some of the features of liver disease including diarrhoea and cutaneous vascular changes. The purpose of this study was to clarify the changes in gastroenteropancreatic hormones related either to chronic alcohol ingestion or to liver disease. There was no difference in fasting or post-prandial hormone release in the alcoholic group without liver disease compared with that found in the normal volunteers, indicating that alcoholism without hepatic complications does not influence gastroenteropancreatic hormone release.
